Wed, 21 Sep 2022 | BUSINESS SALE
Welsh life sciences firm Diurnal is set to be acquired by US neuroscience-focused biopharmaceutical company Neurocrine in a cash deal valued at £48.3 million. The deal is subject to shareholder approval, which is expected to be confirmed next month after the acquisition was recommended by Diurnal’s board.
Diurnal is headquartered in Cardiff and is a pharmaceutical firm working to address patient needs in chronic endocrine (hormonal) diseases. The company is listed on Cardiff’s Alternative Investment Market and includes among its minority shareholders the Welsh Government-owned Development Bank of Wales, which invested in the firm prior to its flotation.
In the six months ending December 31 2021, Diurnal reported £2.13 million in unaudited net product sales and a £7.95 million net loss. The £48.3 million price reflects a valuation of 27.5 pence per share.
Diurnal non-executive chairman Anders Härfstrand commented: “The board of Diurnal is delighted to announce this recommended offer. Diurnal and Neurocrine are highly complementary businesses, and we believe that Neurocrine’s financial and operational resources will substantially accelerate the development of a leading franchise in diseases of cortisol deficiency, benefiting physicians and patients globally.”
“We believe that the acquisition is compelling for Diurnal’s shareholders, given the risks associated with achieving Diurnal’s vision of creating a profitable business, in particular the ongoing commercial rollout of products in Europe and the execution of key clinical studies, in addition to the substantial shareholder dilution that is likely to result from accessing the capital required to deliver this vision.”
The acquisition comes at a time when UK businesses are proving particularly attractive to foreign buyers. A recent ranking named the UK as Europe’s most attractive destination for inbound M&A investment, driven by factors including the UK’s strong recovery from COVID-19 in comparison to EU counterparts and its market-leading position in many key industries.
Furthermore, with the pound recently falling to a 37-year low and the US dollar performing relatively strongly, it seems likely that the UK could be poised to see even more inbound investment from across the Atlantic, as US buyers move to pick up UK firms at low valuations.
Find businesses for sale here.
If you are looking for an exit, we can help!.
A highly reputable clinic in the heart of London, offering an extensive range of non-surgical services for a diverse clientele in its state-of-the-art clinic. The Company has achieved remarkable growth, surpassing its competitors, thanks to the team’...
LEASEHOLD
An exceptional standard of person-centred care for individuals in their homes and 24-hour supported living accommodation (two leased properties).
LEASEHOLD
An opportunity to acquire an independent and family-run care agency that provides 24-hour domiciliary care and support to service users in their home environment on a one-to-one basis.
RELOCATABLE
26
|
Jul
|
Tunnelling construction technology company falls into administration | ADMINISTRATION
A tunnelling construction technology company based in Basing...
26
|
Jul
|
Sumer firm RMT completes second deal of the year | MERGER
RMT Accountants & Business Advisors, which is part of the Su...
25
|
Jul
|
Occupational health service provider secures PE backing for acquisitions | BUSINESS NEWS
A Hull-headquartered provider of occupational health service...
Business Sale Report is your complete solution to finding great acquisition opportunities.
Join today to receive:
All this and much more, including the latest M&A news and exclusive resources
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.